Metformin

Metformin changes glucose handling, including reducing glucose production by the liver and improving the response to insulin. Its diabetes role should not be reframed as proof of a longevity benefit or a guaranteed weight outcome. Different release formulations have different product instructions. ¹

Diarrhea, nausea and stomach discomfort are common concerns. Rare lactic acidosis can be serious, especially in relevant kidney, liver or acute illness contexts. Kidney assessment, vitamin B12 history, heavy alcohol intake and planned contrast procedures belong in the medication review. ¹

Ask why metformin is being considered for the actual diagnosis, which formulation is proposed, and how response and side effects will be assessed. Bring previous lab results and all other glucose-lowering medicines. If the purpose is off-label, ask what evidence supports that particular purpose.

Kidney function helps determine whether metformin can be started or continued because reduced clearance increases the risk of accumulation and lactic acidosis. Acute dehydration, severe infection, low oxygen states, heavy alcohol use, liver disease and certain procedures can also change risk. Contrast imaging and surgery may require a temporary plan based on kidney function and the procedure. Do not create a hold or restart schedule independently; ask the ordering and prescribing teams to document when metformin should stop and resume. ¹

Diarrhea, nausea, gas and abdominal discomfort are common, especially when treatment changes. Persistent symptoms deserve review rather than automatic escalation or abandonment. Longer-term metformin use can lower vitamin B12 levels in some people. Tingling, numbness, anemia, unusual fatigue or a dietary risk may prompt testing, but an energy complaint alone does not prove B12 deficiency. Extended-release and immediate-release tablets have different instructions; do not crush or substitute products without checking the label. ¹

Metformin is approved for type 2 diabetes, not as a general weight-loss drug. Weight change can occur, but it is variable and should not be promised or used as the only measure of whether diabetes treatment is working. Off-label use for conditions such as prediabetes or polycystic ovary syndrome requires a specific rationale and follow-up. Ask which diagnosis is being addressed, which laboratory or symptom outcomes matter, and what would lead to a change in the plan. ¹

Metformin-associated lactic acidosis is rare but serious. Profound weakness, unusual muscle pain, trouble breathing, persistent vomiting, abdominal discomfort, dizziness, feeling cold or a slow or irregular heartbeat requires urgent assessment, especially with kidney dysfunction, dehydration, severe infection or low oxygen. Stop decisions in an acute illness should follow the clinical plan, but emergency symptoms should never wait for a routine appointment. ¹